Compare OVLY & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVLY | TVRD |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.0M | 246.5M |
| IPO Year | N/A | N/A |
| Metric | OVLY | TVRD |
|---|---|---|
| Price | $27.75 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | 8.4K | ★ 125.4K |
| Earning Date | 01-23-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $79,783,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.74 | ★ N/A |
| Revenue Growth | ★ 2.98 | N/A |
| 52 Week Low | $22.70 | $3.74 |
| 52 Week High | $32.24 | $43.65 |
| Indicator | OVLY | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 31.07 |
| Support Level | $27.66 | $4.05 |
| Resistance Level | $28.25 | $4.40 |
| Average True Range (ATR) | 0.45 | 0.27 |
| MACD | -0.04 | 0.63 |
| Stochastic Oscillator | 68.28 | 83.33 |
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.